Portal de Periódicos da CAPES

Artigo Acesso aberto Produção Nacional Revisado por pares

BIBTEX RIS

Prognostic Factors in De Novo Metastatic Renal Cell Carcinoma: A Report From the Latin American Renal Cancer Group

2021; Lippincott Williams & Wilkins; Issue: 7 Linguagem: Inglês

10.1200/go.20.00621

2687-8941

Diego Abreu, Gustavo Franco Carvalhal, Guillermo Gueglio, Ignacio Tobía, P Sánchez García, Álvaro Zúñiga, Luís Meza, Rubén H. Bengió, Carlos H. Scorticati, Ricardo Castillejos, Francisco Rodríguez, Ana María Autran, Carmen Gonzales, Jose Gadu, Alejandro Nolazco, Carlos Ameri, Hamilton de Campos Zampolli, Raúl Langenhin, Diego Muguruza, Marcos Tobías Machado, Pablo Mingote, Juan Yandian, Jorge Clavijo, Lucas Nogueira, Omar Clark, Fernando P. Secín, Agustín Roberto Rovegno, Ana Paula Vilas, Enrique Barrios, Ricardo Decia, Gustavo Cardoso Guimarães, Sidney Glina, Sumanta K. Pal, Óscar Rodríguez, Joan Palou, Philippe E. Spiess, Primo N. Lara, W. Marston Linehan, Antonio Luigi Pastore, Stênio de Cássio Zéqui,

Cancer Genomics and Diagnostics

PURPOSE To assess the effect of clinical and pathological variables on cancer-specific and overall survival (OS) in de novo metastatic patients from a collaborative of primarily Latin American countries. PATIENTS AND METHODS Of 4,060 patients with renal cell carcinoma diagnosed between 1990 and 2015, a total of 530 (14.5%) had metastasis at clinical presentation. Relationships between clinical and pathological parameters and treatment-related outcomes were analyzed by Cox regression and the log-rank method. RESULTS Of 530 patients, 184 (90.6%) had died of renal cell carcinoma. The median OS of the entire cohort was 24 months. American Society of Anesthesiology classification 3-4 (hazard ratio [HR]: 1.64), perirenal fat invasion (HR: 2.02), and ≥ 2 metastatic organ sites (HR: 2.19) were independent prognostic factors for 5-year OS in multivariable analyses. We created a risk group stratification with these variables: no adverse risk factors (favorable group), median OS not reached; one adverse factor (intermediate group), median OS 33 months (HR: 2.04); and two or three adverse factors (poor risk group), median OS 14 months (HR: 3.58). CONCLUSION Our study defines novel prognostic factors that are relevant to a Latin American cohort. With external validation, these easily discerned clinical variables can be used to offer prognostic information across low- and middle-income countries.